TriSalus Life Sciences, Inc. (TLSI)

NASDAQ | Biotech | Medical technology and immunotherapy
Free
No email, no account, no signup.
Pulling latest news for TriSalus Life Sciences, Inc.…
Bull
Bear
Preliminary read — single AI model. The deep report cross-checks with four.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Medical technology and immunotherapy
Market Cap
$272M
We're already tracking TriSalus Life Sciences, Inc. — here are the latest events we've registered

Recent News

  • On May 4, 2026, the company announced the launch of the PREDICTT clinical trial to evaluate pressure-enabled drug delivery in liver tumors. This follows the April 2026 appointment of Dr. Richard Marshall as Chief Medical Officer, effective June 29, 2026.
Want to know how this news affects TriSalus Life Sciences, Inc.? Order the analysis.
Order analysis – $4.99

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of TriSalus Life Sciences, Inc. will be delivered in the same format.

Sample analyses in the same sector

Click to see what a complete analysis looks like.

Swedish Orphan Biovitrum AB (publ)
SOBI
HOLD
Cereno Scientific B
CRNO B
HOLD
Liquidia Corporation
LQDA
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Halozyme Therapeutics, Inc.
HALO
BUY
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
TriSalus Life Sciences, Inc. (TLSI)
Fresh analysis on demand
Order analysis – $4.99
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.